Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator.

BACKGROUND

The prognostic value of CTCs for post-LT tumor recurrence remains insufficiently studied, and the associations between CTCs and immunosuppressants remain unclear.

METHODS

This study analyzed 277 HCC patients undergoing liver transplantation. MCTC and ECTC levels were measured from the day of surgery to one month postoperatively. Prognostic outcomes were compared across patients with varying MCTC levels, with subgroup analysis based on the presence or absence of major portal vein tumor thrombus. Differences in MCTC dynamics and outcomes were further evaluated across immunosuppressant regimens.

RESULTS

Patients with low MCTC levels demonstrated better recurrence-free survival (RFS) than those with high MCTC levels (p = 0.022), a trend observed in both the PVTT subgroup (p = 0.023) and the non-PVTT subgroup (p = 0.046). Patients with a reduction in MCTC levels at the second measurement had significantly better prognoses compared to those without a reduction (p = 0.03). The use of sirolimus was associated with a decrease in MCTC levels (p = 0.017), and patients receiving sirolimus exhibited improved survival compared to those not using sirolimus (p = 0.033). Sirolimus also extended post-recurrence survival (p = 0.0052).

CONCLUSION

MCTC levels serve as an effective predictor of tumor recurrence following liver transplantation for HCC. Sirolimus reduces MCTC levels and extends post-recurrence survival.